Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Employees

596

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/09/26	HK$21.22	+1.82%	101,600
01/09/26	HK$20.84	-6.04%	73,000
31/08/26	HK$22.18	+3.16%	100,700
28/08/26	HK$21.50	-2.45%	102,900
27/08/26	HK$22.04	+0.36%	100,000

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

18.19CNY

Average target price

23.26CNY

Spread / Average Target

+27.89%

Consensus

Net sales - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. 09:08:07 02/09/2026 BST			5-day change	1st Jan Change
21.22 ^HKD	+1.82%		-7.09%	-30.38%

08-27	Medtide Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-31	Medtide Names CFO	MT

Market Cap	2.58B 3.01B 384M 331M 312M 284M 531M 36.26B 535M 3.69B 1.43B 18.54B 1.44B 1.41B 60.89B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	1.89B 2.2B 281M 242M 228M 208M 388M 26.51B 391M 2.7B 1.05B 13.55B 1.05B 1.03B 44.52B	EV / Sales 2026 *	2.97x	EV / Sales 2027 *	2.2x
Free-Float	19.48%	Yield 2026 *	-	Yield 2027 *	-

08-27	Medtide Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-31	Medtide Names CFO	MT
07-31	Medtide Inc. Announces Appointment of Ding Lijun as Chief Financial Officer, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Management Changes, Effective July 31, 2026	CI
07-31	Medtide Inc. Announces Change of Principal Place of Business in Hong Kong	CI
07-31	Medtide Inc. Provides Group Earnings Guidance for the Six Months Ended Year Ended June 30, 2026	CI
06-30	95,524,875 H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 29-JUN-2026.	CI
06-18	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI
03-30	Medtide Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-09	Medtide Completes Hong Kong-Listed Share Full Circulation	MT
02-26	Medtide Forecasts Higher 2025 Profit on Back of Up to 32% Rise in Revenue	MT
02-25	Medtide Inc. Provides Preliminary Group Earnings Guidance for the Year Ended December 31, 2025	CI
02-06	Medtide Gets CSRC Nod for Hong Kong Share Full Circulation	MT

1 day	+1.82%
1 week	-7.09%
Current month	-4.33%
1 month	-5.77%
3 months	+2.22%
6 months	-17.17%
Current year	-30.38%

Medtide Inc. Share Price

Stocks

3880

CNE100006S86

Biotechnology & Medical Research

Valuation : Medtide Inc.

Chart: Medtide Inc.

Latest news : Medtide Inc.

Press Releases : Medtide Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Medtide Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Net sales - Rate of surprise

1 week	20.62	23
1 month	19.8	24.5
Current year	19	30.46
1 year	19	37.8
3 years	19	41.72
5 years	19	41.72
10 years	19	41.72

Manager	Title	Age	Since
Qi Xu CEO	Chief Executive Officer	58	10/06/2020
Li Jun Ding DFI	Director of Finance/CFO	50	30/07/2026
Wei Qun Xu DFI	Director of Finance/CFO	53	30/09/2020

Director	Title	Age	Since
Qi Xu CHM	Chairman	58	10/06/2020
Xiang Li Li BRD	Director/Board Member	51	26/01/2022
Xiang Li BRD	Director/Board Member	63	26/01/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/03/26	Qi Xu	Other	Chief Executive Officer	68,201,112	48.0967%
09/03/26	Xiang Li Li	Other	Director	68,201,112	48.0967%
09/03/26	Qi Xu	Other	Chief Executive Officer	68,201,112	48.0967%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MEDTIDE INC.	+1.82%	-7.09%	-42.99%	-	377M
LONZA GROUP AG	+0.97%	-0.75%	+3.51%	+17.79%	49.74B
REVOLUTION MEDICINES, INC.	+0.14%	-2.60%	+430.82%	+522.84%	44.98B
IQVIA HOLDINGS INC.	+2.60%	+1.44%	+44.38%	+20.10%	42.52B
BEONE MEDICINES AG	+1.07%	-3.72%	+8.97%	+76.63%	40.78B
CELLTRION, INC.	-0.90%	-1.74%	+15.20%	+48.44%	32.89B
ASCENDIS PHARMA A/S	+2.53%	+6.24%	-	-	17.09B
MEDPACE HOLDINGS, INC.	+1.57%	-4.63%	+24.73%	+122.71%	16.28B
EUROFINS SCIENTIFIC SE	+1.70%	-0.05%	+18.53%	+28.09%	14.4B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.80%	-1.75%	+79.81%	+41.93%	13.48B
Average	+1.40%	-3.06%	+64.77%	+109.82%	27.25B
Weighted average by Cap.	+1.11%	-2.26%	+94.09%	+129.15%

	2026 *	2027 *
Net sales	636M 742M 94.58M 81.6M 76.86M 70.03M 131M 8.93B 132M 910M 353M 4.57B 355M 347M 15.01B	807M 942M 120M 104M 97.62M 88.94M 166M 11.35B 167M 1.16B 449M 5.8B 451M 441M 19.06B
Net income	-	-
Net Debt	-693M -809M -103M -89M -83.84M -76.39M -143M -9.75B -144M -993M -385M -4.98B -387M -379M -16.37B	-802M -936M -119M -103M -97.03M -88.41M -165M -11.28B -166M -1.15B -446M -5.77B -448M -439M -18.94B